dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse

This website has run out of funding so feel free to contribute if you can afford it (see footer)

Author Topic: Breaking news: FDA Approves Non-Opioid Painkiller With No Addiction Risk  (Read 956 times)

Offline Chip (OP)

  • Server Admin
  • Hero Member
  • *****
  • Administrator
  • *****
  • Join Date: Dec 2014
  • Location: Australia
  • Posts: 6925
  • Reputation Power: 0
  • Chip has hidden their reputation power
  • Gender: Male
  • Last Login:Today at 08:44:44 AM
  • Deeply Confused Learner
  • Profession: IT Engineer
Source: https://www.forbes.com/sites/antoniopequenoiv/2025/01/30/fda-approves-non-opioid-painkiller-with-no-addiction-risk/?utm_medium=browser_notifications&utm_source=pushly&utm_campaign=6208007

Jan 30, 2025, 07:55pm EST

The FDA approved Vertex Pharmaceuticals’ “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA considered the start of a new class of non-addictive medicines

Key Facts

The FDA approved Journavx for adults with moderate to severe pain after expediting the drug’s development and review.

The painkiller, which has a lofty list price of $15.50 per pill, blocks pain signals before they reach the brainlike opioids that reduce pain by latching on to receptors to the brain and create the risk of addiction.

Acute pain that can be treated by Journavx has been often treated with analgesics that might contain opioids, according to the FDA.

What Are Side Effects Of Journavx?

Journavx’s commonly reported side effects include nausea, rash, itching, headache, constipation and muscle spasms.

What To Watch For

Vertex plans to conduct a late-stage study of Journavx that could potentially lead to the drug being approved for chronic pain, which the FDA defines as pain that “persists for more than three months or pain that lasts more than one month beyond the normal healing time.”

Big Number

$1 billion. That is how much Wall Street analysts have estimated the painkiller could produce in annual sales.

Key Background

Journavx’s approval marks a significant development in coming up with alternatives to opioids, which has been sought as opioid use has resulted in a wave of drug addictions and overdoses among the American public.

Deaths involving opioids totaled 80,816 in 2021, nearly 11,000 more than 2020, according to the Centers for Disease Control and Prevention.

In 2020, an estimated 2.7 million people above the age of 11 had an opioid use disorder in the past 12 months, according to the 2020 National Survey on Drug Use and Health.
« Last Edit: February 01, 2025, 08:35:41 AM by Chip »
friendly
0
funny
0
informative
0
agree
0
disagree
0
like
0
dislike
0
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
Our Discord Server invitation link is https://discord.gg/jB2qmRrxyD

Offline smfadmin

  • SMF (internal) Site
  • Administrator
  • Full Member
  • *****
  • Join Date: Dec 2014
  • Location: Management
  • Posts: 208
  • Reputation Power: 0
  • smfadmin has hidden their reputation power
  • Last Login:Today at 06:06:23 AM
  • Supplied Install Member
Re: Breaking news: FDA Approves Non-Opioid Painkiller With No Addiction Risk
« Reply #1 on: February 02, 2025, 07:31:50 AM »
https://www.nature.com/articles/d41586-025-00274-1?utm_source=Live+Audience&utm_campaign=7f8f44a224-nature-briefing-daily-20250131&utm_medium=email&utm_term=0_b27a691814-7f8f44a224-498702756

The US Food and Drug Administration has approved the non-opioid painkiller suzetrigine for short-term pain management.

Suzetrigine is the first pain drug given a regulatory nod in more than 20 years that works through a brand-new mechanism, without the risks of addiction or sedation.

Unlike opioids, the drug doesn’t act in the brain, instead blocking certain sodium channels in pain-sensing cells in the peripheral nervous system.

When it comes to chronic pain — where the need for safer, non-opioid alternatives is most pressing — trials haven’t proven suzetrigine’s efficacy, nor were they long enough to rule out side effects from long-term use.
« Last Edit: February 02, 2025, 07:36:46 AM by smfadmin »
friendly
0
funny
0
informative
0
agree
0
disagree
0
like
0
dislike
0
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
measure twice, cut once

Tags:
 

Related Topics

  Subject / Started by Replies Last post
2 Replies
12261 Views
Last post October 31, 2015, 10:50:04 PM
by Thoms
1 Replies
10281 Views
Last post November 05, 2015, 12:45:22 PM
by Anti-hero
14 Replies
2793 Views
Last post January 15, 2016, 06:43:50 PM
by Sand and Water
0 Replies
462 Views
Last post January 17, 2016, 12:06:52 PM
by Z
0 Replies
474 Views
Last post January 18, 2016, 11:50:33 AM
by Z
6 Replies
1260 Views
Last post February 02, 2016, 09:20:12 PM
by whiteheat
0 Replies
620 Views
Last post January 22, 2016, 01:16:51 PM
by Z
10 Replies
18514 Views
Last post February 01, 2016, 01:29:16 PM
by robojunkie
0 Replies
10789 Views
Last post October 21, 2016, 02:56:05 AM
by sickboy
0 Replies
9590 Views
Last post September 29, 2019, 05:50:30 AM
by Chip


dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse





TERMS AND CONDITIONS

In no event will d&u or any person involved in creating, producing, or distributing site information be liable for any direct, indirect, incidental, punitive, special or consequential damages arising out of the use of or inability to use d&u. You agree to indemnify and hold harmless d&u, its domain founders, sponsors, maintainers, server administrators, volunteers and contributors from and against all liability, claims, damages, costs and expenses, including legal fees, that arise directly or indirectly from the use of any part of the d&u site.


TO USE THIS WEBSITE YOU MUST AGREE TO THE TERMS AND CONDITIONS ABOVE


Founded December 2014
SimplePortal 2.3.6 © 2008-2014, SimplePortal